Video
Juan Basterra, CEO at Mikrobiomik, talks about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
Video
Sponsored by
Nina Vinot (TargEDys International Sales Director) talks about a new promising way to isolate, study and bring to the market innovative probiotics.
Karl Alex Hedin (Technical University of Denmark) talks about the potential role of genetically engineering Saccharomyces boulardii to produce an anti-obesity peptide.
Gwenael Jan (STLO - INRAE, France) talks about the growing interest and knowledge of Propionibacteria, a peculiar actinobacteria that has the potential to become a next generation probiotic.
Amine Zorgani (Microbiome Mavericks) talks about the importance of the skin microbiome in maintaining skin health and the need for continued research in this field.
Elisabetta Caselli, University of Ferrara (Italy), talks about a new and innovative use of probiotics to modulate the "hospital microbiome” in order to reduce the use of chemical disinfectants.
George Paraskevakos, Executive Director at International Probiotics Association, talks about probiotic and live biotherapeutic products market evolution and perspective.
Philippe Langella, Research Director at the French National Institute of Agricultural Research, discussed the potential of Faecalibacterium Prausnitzii as Live Biotherapeutics for several disease.
Together with Professor Lorenzo Morelli we focused on the significant role of diet and the microbiome in terms of health benefits, food production, and agri-industry systems.
Microbiomepost interviewed Lorenzo Drago, from University of Milan, during the ESGE DAYS congress, held recently in Dublin.
